Sumitomo Pharma Co., Ltd.
Stock Price Chart
2026/11/06 12:54 UpdatedPrice Trend
2026/11/06 12:54 UpdatedPrice & Trading Details
2026/11/06 12:54 UpdatedPRICE
TRADING
Analyst Recommendations 7 analysts
Updated 2026/11/01Earnings Calendar
Updated 2026/11/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/10/29 | ¥28.20 | ¥47.46 | +68.3% |
| 2026/07/30 | ¥19.13 | ¥39.02 | +104.0% |
| 2026/05/13 | ¥-15.24 | ¥-2.04 | +86.6% |
| 2026/01/30 | ¥-0.87 | ¥22.19 | +2,650.6% |
Shareholder Composition
Updated 2026/11/01Top Mutual Funds / ETFs
Updated 2026/11/01Major Holders
Updated 2026/11/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
3.3M | +22.19% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
2.2M | +36.64% | |
|
T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Intl Discovery Fd.
|
2.2M | 0.00% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.7M | +1.32% | |
|
College Retirement Equities Fd.-College Retirement Equities Fd. - Tota
|
1.3M | +8.65% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
841.0K | +0.82% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
274.2K | +1.00% |
Dividend History
Updated 2026/11/01| Year | Dividend | Change |
|---|---|---|
| 2023 | ¥7 | -75.0% |
| 2022 | ¥28 | 0.0% |
| 2021 | ¥28 | 0.0% |
| 2020 | ¥28 | -20.0% |
| 2019 | ¥35 | - |
Financial Performance
2026/11/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥560,035M | ¥555,544M | ¥314,558M | ¥398,832M |
| Gross Profit | ¥402,908M | ¥376,625M | ¥187,981M | ¥245,395M |
| Operating Income | ¥60,234M | -¥76,979M | -¥354,836M | ¥29,709M |
| Pretax Income | ¥86,011M | -¥44,761M | -¥318,837M | ¥31,111M |
| Net Income | ¥56,413M | -¥74,512M | -¥314,969M | ¥23,634M |
| EPS | ¥141.99 | -¥187.55 | -¥792.79 | ¥59.49 |
| Operating Margin | 10.76% | -13.86% | -112.80% | 7.45% |
| Balance Sheet | ||||
| Total Assets | ¥1,308,007M | ¥1,134,742M | ¥907,506M | ¥742,604M |
| Total Equity | ¥607,888M | ¥406,749M | ¥156,063M | ¥169,479M |
| Total Liabilities | ¥700,119M | ¥727,993M | ¥751,443M | ¥573,125M |
| Cash | ¥202,984M | ¥143,478M | ¥29,047M | ¥23,116M |
| Interest-bearing Debt | ¥269,048M | ¥334,716M | ¥418,884M | ¥305,422M |
| Equity Ratio | 46.47% | 35.85% | 17.20% | 22.82% |
| D/E Ratio | 0.44 | 0.82 | 2.68 | 1.80 |
| Cash Flow | ||||
| Operating CF | ¥31,239M | ¥11,937M | -¥241,893M | ¥16,500M |
| Investing CF | -¥18,278M | ¥52,419M | ¥33,036M | ¥99,754M |
| Financing CF | -¥21,426M | -¥146,817M | ¥77,851M | -¥108,836M |
| Free CF | ¥17,745M | -¥805M | -¥257,623M | ¥3,470M |
| Efficiency | ||||
| ROE | 9.28% | -18.32% | -201.82% | 13.95% |
| ROA | 4.31% | -6.57% | -34.71% | 3.18% |
Latest IR Information
-
Supplementary Materials for FY2026 Q2 Financial Results
Published IFRS-based supplementary materials for FY2026 Q2. Revenue was 266.5 hundred million yen, up 17.3% year-over-year; core operating profit declined sharply to 42.1 hundred million yen; overseas sales ratio expanded to 83.2%. Earnings forecasts were revised.
Read more -
Notice of Differences Between Consolidated Earnings Guidance and Actual Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 and Revision to Full-Year Consolidated Earnings Guidance
Second-quarter results exceeded the prior guidance, prompting an upward revision to the full-year forecast. Revenue is revised to 565,000 million yen, core operating profit to 105,000 million yen, operating profit to 104,000 million yen, and net income attributable to owners...
Read more -
Notice of Revision to Year-End Dividend Forecast for Fiscal Year Ending March 2027
Revised the year-end dividend forecast for the fiscal year ending March 2027 to 15 yen per share. No interim dividend was paid. No dividend was paid in the prior fiscal year. Final decision will be made based on future business...
Read more -
Financial Summary for the Second Quarter of Fiscal Year Ending March 2027 (IFRS) (Consolidated)
For the second quarter of the fiscal year ending March 2027, revenue was 266,490 million yen (up 17.3% year-over-year), core operating profit was 421 hundred million yen, and interim profit attributable to owners of the parent was 38,238 million yen....
Read more -
FY2026 Q2 Earnings Presentation Materials
In the FY2026 Q2 overview, revenue was revised upward for the full-year forecast. Core operating profit increased, driven by expanded contributions from key products such as Orgovix in the US market. The full-year forecast was partially revised and the year-end...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥2,243
Rating Score: 2.00 (Based on 7 analysts)
※1=Strong Buy, 5=Strong Sell
Sumitomo Pharma Co., Ltd. (SMDPY) Seasonal returns chart - Yahoo Finance - Yahoo Finance Singapore ↗
Company Information
About
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
